Cargando…
A DNA methylation signature discriminates between excellent and non-response to lithium in patients with bipolar disorder type 1
Lithium (Li) is the cornerstone maintenance treatment for bipolar disorders (BD), but response rates are highly variable. To date, no clinical or biological marker is available to reliably define eligibility criteria for a maintenance treatment with Li. We examined whether the prophylactic response...
Autores principales: | Marie-Claire, C., Lejeune, F. X., Mundwiller, E., Ulveling, D., Moszer, I., Bellivier, F., Etain, B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376060/ https://www.ncbi.nlm.nih.gov/pubmed/32699220 http://dx.doi.org/10.1038/s41598-020-69073-0 |
Ejemplares similares
-
Methylomic Biomarkers of Lithium Response in Bipolar Disorder: A Proof of Transferability Study
por: Marie-Claire, Cynthia, et al.
Publicado: (2022) -
Methylomic biomarkers of lithium response in bipolar disorder: a clinical utility study
por: Marie-Claire, C., et al.
Publicado: (2023) -
Can an Integrated Science Approach to Precision Medicine Research Improve Lithium Treatment in Bipolar Disorders?
por: Scott, Jan, et al.
Publicado: (2018) -
Circadian biomarkers in patients with bipolar disorder: promising putative predictors of lithium response
por: Geoffroy, Pierre Alexis, et al.
Publicado: (2014) -
DNA Methylation as a Biomarker of Treatment Response Variability in Serious Mental Illnesses: A Systematic Review Focused on Bipolar Disorder, Schizophrenia, and Major Depressive Disorder
por: Goud Alladi, Charanraj, et al.
Publicado: (2018)